Mydecine Innovations Announces Closing of Prospectus Supplement Financing

Mydecine Innovations Announces Closing of Prospectus Supplement Financing

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that further to the Company's news release dated September 15, 2023, the Company has closed its previously announced offering by way of prospectus supplement (the " Offering "). Pursuant to the Offering, the Company issued 18,7500,000 common shares of the Company (each a " Share ") at a price of $0.20 per Share for aggregate gross proceeds of $3,7500,000.

The Offering was completed pursuant to a shelf prospectus supplement to the Company's Final Short Form Base Shelf Prospectus for the province of Québec and Amended and Restated Final Short Form Base Shelf Prospectus for each of the provinces of Canada, dated January 28, 2022.

The Company will use the proceeds of the Offering as described in the Prospectus Supplement.

The Prospectus Supplement and Base Shelf Prospectus are available on the Company's profile on the System for Electronic Document Analysis and Retrieval + (SEDAR+) at www.sedarplus.com .

About Mydecine Innovations Group, Inc.

Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing MYCO-006—short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others.

Learn more at https://www.mydecine.com .

For more information, please contact:

Media Contact:
pr@mydecineinc.com

Investor Relations:
investorrelations@mydecineinc.com

On behalf of the Board of Directors:

Joshua Bartch, Chief Executive Officer

contact@mydecineinc.com

For further information about Mydecine Innovations Group, Inc., please visit the Company's profile on SEDAR+ at www.sedarplus.com or the Company's website at www.mydecine.com .

This news release contains forward-looking information about Canadian securities laws regarding the Company and its business. It relates to future events or performance and reflects management's expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect," "intends," "anticipated," "believes," or variations (including negative variations) of such words and phrases or by stating that specific actions, events, or results "may," "could," "would," or "will" be taken, occur, or be achieved.

Such forward-looking statements reflect management's beliefs and are based on assumptions and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to protect and enforce its intellectual property adequately, the Company's ability to bring its products to commercial production, the continued growth of the global adaptive pathway medicine, natural health products, and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale, and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause effects not to be as anticipated, estimated, or intended. There can be no assurance that such information will be accurate, as actual results and future events could differ materially from those anticipated. These forward-looking statements are made as of the date hereof. The Company is not obligated to update or revise them to reflect new events or circumstances as required under applicable securities legislation.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.


MYDECINE INNOVATIONS GROUP INC.
Suite 810–789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T: 604-687-2038


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

MYCO:CC
The Conversation (0)
Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company's MYCO-005 and MYCO-006 families.

MYCO-005 Notice of Allowance: Aza-Substituted Psilocin Analogs and Methods of Synthesising the Same Unique Compound

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mydecine Innovations Group Announces Director Resignation

Mydecine Innovations Group Announces Director Resignation

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors.

The Company is in the process of identifying a qualified replacement director and will make any necessary announcements in due course.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for their MYCO-005 compound, "Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same Unique Compound (US20230348380A1)".

This Composition of Matter patent underscores Mydecine's commitment to innovation in mental health therapeutics. MYCO-005, a novel compound, that mimics psilocin as an improved version engineered to act therapeutically similar to psilocin while dramatically reducing highly undesirable side effects from long-term sustained use of psilocybin and almost all-known classical serotonin agonists (LSD, DMT, etc.), specifically addressing valvular fibrosis concerns recognised by leading clinicians and FDA regulators. MYCO-005 is designed with selective binding to 5-HT2A receptors and does not bind to 5-HT2B receptors for both macro and microdosing.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Mydecine Announces Update Regarding the Special Access Program

Mydecine Announces Update Regarding the Special Access Program

MYDECINE INNOVATIONS GROUP INC. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company's news release of January 13, 2022 (the " Prior Release ") wherein the Company announced it would be launching the Special Access Support and Supply Program (" SASSP ") to provide products and services to physicians, clinics, and hospitals in Canada who are looking to treat patients through psychedelic-assisted psychotherapy.

The Company would like to clarify that the access to Health Canada's Special Access Program (the " Program ") to assist potential patients with the use of Psilocybin and/or MDMA is exclusively through its partner, Applied Pharmaceutical Innovation (" API ") pursuant to the Health Canada license granted to Dr. Raimar Loebenberg (the " Partnership "). Pursuant to the Partnership, API may provide patients access to certain controlled substances, including Psilocybin and/or MDMA, however, Mydecine does not directly have the ability to grant patients access to controlled substances through the Program.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Canadian Securities Exchange Reports October 2023 Performance Figures

Canadian Securities Exchange Reports October 2023 Performance Figures

The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2023.

October 2023 Operating Statistics

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×